Shareholders to Vote on Massive Authorized Share Increase Post-Reverse Split

summarizeSummary

Silo Pharma has filed a definitive proxy statement for its annual meeting, where shareholders will vote on a proposal to increase authorized common stock by over 37 times, setting the stage for significant future dilution.

check_boxKey Events · Corporate Governance and Compliance · SILO

• Shareholder Meeting Scheduled

  The Annual Meeting of Shareholders is scheduled for August 14, 2026, where key corporate proposals will be voted upon.

• Massive Increase in Authorized Shares Proposed

  The company proposes to increase its authorized common stock from 6,666,667 to 250,000,000 shares. This follows a preliminary proxy statement filed on June 18, 2026, and finalizes the proposal for a shareholder vote.

• Significant Potential Dilution

  If all newly authorized shares were issued, it would result in a potential dilution of over 22,051% for existing shareholders, based on 1,128,610 shares currently outstanding.

• Purpose for Capital Raising and Acquisitions

  The increased authorization is intended to provide flexibility for future financing transactions, strategic investments, mergers, acquisitions (including in vitro fertilization clinics to reach cash flow breakeven), and equity incentive plans.

auto_awesomeAnalysis · SILO · Life Sciences

Silo Pharma is seeking shareholder approval to increase its authorized common stock from 6.66 million to 250 million shares. This represents a potential dilution of over 22,000% if all authorized shares were issued, relative to the current outstanding shares. This substantial increase, coming shortly after a 1-for-15 reverse stock split, indicates the company's intent to raise significant equity capital or pursue acquisitions, which will heavily dilute existing shareholders. For a micro-cap company, this level of potential dilution is a critical event, signaling a major shift in capital structure and future financing strategy.